Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
8 Biotech Penny Stocks for Investors to Watch
11:54am, Wednesday, 10'th Mar 2021
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q4 2020 Results - Earnings Call Transcript
12:12am, Wednesday, 03'rd Mar 2021
Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q4 2020 Results - Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Tops Revenue Estimates
06:55pm, Tuesday, 02'nd Mar 2021
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring
07:21am, Sunday, 21'st Feb 2021
Here's why this stock's big run-up in recent months could be just the beginning.
RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today
02:48pm, Thursday, 18'th Feb 2021
A newly announced deal between Rigel Pharmaceuticals and sector behemoth Eli Lilly has RIGL stock climbing in trading today. The post RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today appeared f
Why Rigel Pharmaceuticals Stock Is Jumping Today
12:40pm, Thursday, 18'th Feb 2021
The company is teaming up with Eli Lilly on the development of a promising immune disease drug.
RIGL Stock Price Increases Over 20% Pre-Market: This Is Why It Happened
08:36am, Thursday, 18'th Feb 2021
The stock price of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) increased over 20% pre-market as of 8:31 AM ET. This is why it happened.
Rigel Pharma shares soar 39% premarket on news of deal with Eli Lilly
06:52am, Thursday, 18'th Feb 2021
Rigel Pharmaceuticals Inc. shares soared 39% in premarket trade Thursday, after the company said it has agreed to partner with Eli Lilly and Co. in developing RIPK1 Inhibitors to treat immunological a
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
02:45pm, Friday, 29'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint
Rigel Still Looks Modestly Undervalued Despite The Recent Rally
11:09am, Monday, 25'th Jan 2021
Rigel's value proposition revolves solely around growing sales of its already approved Tavalisse for ITP in the US and worldwide and getting the label extended to include wAIHA. Tavalisse sales growth
Rigel Pharmaceuticals Provides Business Update
07:30am, Monday, 11'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary total revenue, TAVALISSE® (fostamatinib d
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Thursday, 07'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedu
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals (RIGL) Stock?
09:47am, Monday, 21'st Dec 2020
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharma: Useful For Some Patients, But Does Not Impress As An Investment
04:22am, Tuesday, 08'th Dec 2020
Rigel's approved drug Tavalisse can be useful to cITP patients in a third line setting, but the market isn't huge. Current lead indication WIHA is not large either, and the same safety issues will mak
